New York Life Investment Management LLC increased its position in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 91.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,015 shares of the medical instruments supplier’s stock after buying an additional 10,042 shares during the quarter. New York Life Investment Management LLC’s holdings in Insulet were worth $2,742,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming lifted its stake in Insulet by 34.6% in the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after buying an additional 73 shares during the last quarter. Basecamp Wealth Advisors LLC boosted its holdings in shares of Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 102 shares during the period. Elevation Wealth Partners LLC boosted its holdings in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 104 shares during the period. Pinnacle Associates Ltd. grew its position in shares of Insulet by 6.1% during the third quarter. Pinnacle Associates Ltd. now owns 1,855 shares of the medical instruments supplier’s stock worth $242,000 after acquiring an additional 107 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC grew its position in shares of Insulet by 4.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 3,194 shares of the medical instruments supplier’s stock worth $429,000 after acquiring an additional 134 shares during the last quarter.
Insulet Stock Performance
Insulet stock traded up $3.19 during mid-day trading on Friday, reaching $152.48. 1,590,709 shares of the company were exchanged, compared to its average volume of 1,354,922. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The firm’s 50-day simple moving average is $142.14 and its two-hundred day simple moving average is $173.54. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. The firm has a market cap of $10.58 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 1.14 and a beta of 1.06.
Insulet (NASDAQ:PODD – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company’s revenue was up 19.2% on a year-over-year basis. During the same period last year, the business posted $1.24 EPS. Equities analysts predict that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on PODD shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 target price on shares of Insulet in a report on Wednesday, November 4th. Sanford C. Bernstein increased their price target on shares of Insulet from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Royal Bank Of Canada increased their price target on shares of Insulet from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. UBS Group raised their price objective on shares of Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Finally, Canaccord Genuity Group dropped their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Insulet currently has an average rating of “Hold” and a consensus target price of $185.67.
Read Our Latest Stock Analysis on Insulet
Insulet Profile
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
See Also
- Five stocks we like better than Insulet
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
